Back to Agendas
[V2-S1] Network Meta-Analysis: New Analytical Approaches in HTA and Drug Development - Introduction of methodology and its application
Session Chair(s)
Koji Oba, PhD
Associate Professor, Dept of Biostatistics, School of Public Health
The University of Tokyo, Japan
“Network meta-analysis” has attracted much attention as a new effective approach in drug development. In this session, we would like to show you how effective network meta-analysis is for statisticians and non-statisticians by looking at several examples. Network meta-analysis is the methodology of generalizing the meta-analysis of the comparison between two drugs. It can provide the following effective information by combining the study results with more than two drugs (e.g. Drug A vs Drug B, Drug B vs Drug C, Drug A vs Drug C). (i) In-direct pairwise comparison of two drugs; even if no direct comparison results available. (ii) Higher precision of treatment difference between two drugs; by combining all of the study results of direct and indirect pairwise comparison. The results from the network meta-analysis can be widely used when comparing new drug in development with a standard drug or determining margin of non-inferiority or biosimilar studies.
Speaker(s)
Application and Consideration of Network Meta-analysis for Effectiveness Evaluation of Pharmaceutical Product
Yosuke Fujii, PhD
Pfizer Japan Inc., Japan
Application of Network Meta-Analysis Aiming to Establishment of Target Product Profile
Shumpei Arano
Japan Tobacco Inc., Japan
Analytical Specialist
Implementation of Bayesian Network Meta-analysis to Improve Medical Product Development
Karen Lynn Price, PhD
Eli Lilly and Company, United States
Senior Research Fellow, Statistical Innovation Center/Design Hub
Have an account?